The Moat Index
Compare moats, side by side.
Two to four companies, scored on the same five investor questions from their SEC filings — so the comparison is apples to apples. The method is fully public.
CBLL · Healthcare · Narrow moat
On the watchlist
The returnsOnCapital component abstained: Not enough years of ROIC data to score returns on capital. The other four 20% weights were renormalized over the scored 80%.
BIOE · Healthcare · Narrow moat
On the watchlist
The returnsOnCapital component abstained: Not enough years of ROIC data to score returns on capital. The other four 20% weights were renormalized over the scored 80%.
| Measure | CBLL | PGNY | BIOE | DGX |
|---|---|---|---|---|
| Moat Score (0–100) | 61 (highest) | 61 (highest) | 61 (highest) | 61 (highest) |
| Methodology version | moat-index@2.0.0 | moat-index@2.0.0 | moat-index@2.0.0 | moat-index@2.0.0 |
| Business trend | 70 | 78 (highest) | 65 | 77 |
| Pricing power | 100 (highest) | 30 | 57 | 56 |
| Returns on capital | — | 58 (highest) | — | 30 |
| Balance-sheet safety | 28 | 100 (highest) | 99 | 66 |
| Capital discipline | 47 | 42 | 24 | 77 (highest) |
| Price vs. high estimate | No price data | 307% above high estimate | No price data | 110% above high estimate (largest discount to high estimate) |
| Market cap | $690.9M | $2.6B | $10.3M | $22.8B |
| Moat tier | Narrow moat | Narrow moat | Narrow moat | Narrow moat |
| Filings as of | FY2025 | FY2025 | FY2025 | FY2025 |